P3.02-002 Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients
نویسندگان
چکیده
منابع مشابه
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC
INTRODUCTION In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (previously published). Here, we report EGFR mutation analyses of plasma-derived, circulating-free tumor DNA. METHODS Mandatory tumor and duplicate ...
متن کاملBeyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
PURPOSE Treatment and clinical-outcomes were described in a sub-cohort of non-small-cell lung cancer (NSCLC) patients with disease-progression (PD) after epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) treatment. PATIENTS AND METHODS We retrospectively analyzed a single-institutional EGFR mutation positive (EGFRmut+) NSCLC cohort for post-TKI-PD management, and assessed overall...
متن کاملOutcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
Background Several mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC have been described including the T790M mutation and MET amplification. Whereas T790M mutation confers prolonged survival and sensitivity to 3rd generation TKIs, data are lacking on clinical features and outcome of MET-driven resistant EGFR-mutated NSCLC patients. Methods Patie...
متن کاملEGFR expression in NSCLC
E pidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is frequently overexpressed in nonsmall cell lung cancer (NSCLC). These receptors play an important role in tumour cell survival and activated phosphorylated EGFR results in the phosphorylation of downstream proteins that cause cell proliferation, invasion, metastasis, and inhibition of apoptosis. Expression appears to be dep...
متن کاملLiquid-Based Cytological Samples for Detecting EGFR Mutations in Chinese Patients with NSCLC
Activating mutations in epidermal growth factor receptor (EGFR) gene confer dramatic sensitivity to EGFR TKIs (Rich et al., 2004). Several large randomized phase III studies consistently showed that EGFR-TKIs, such as gefitinib, erlotinib or afatinib achieved significantly higher response rates and longer progression-free survival (PFS) compared to standard chemotherapy and should be regarded a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2017.09.1531